Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Manufacturing Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and ...
Wanbangde Pharmaceutical Holding Group reported revenue of 1.44 billion CNY for fiscal year 2024, down 6.4% from fiscal year 2023, and net income of 55.44 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 263.44 million CNY, down 18.6% from a year before. Its largest business segment, Pharmaceutical Divison, brought in 68% of segment revenue in fiscal year 2024; China was the largest region with 78%.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.